# Ellerston Australian Emerging Leaders Fund - Class A Units



Monthly Report as at 31 May 2025

APIR Code: ECL6748AU | ARSN 647 979 333



Portfolio of 30-60 smaller companies built through an active, research-driven investment approach.



Focus on companies which have a sound business franchise with an attractive earnings profile, which operate in growth industries and trade at a discount to valuation.



Aims to outperform the Benchmark over a rolling three-year period.

# **Performance Summary**

Performance	1 Month	3 Months	1 Year	3 Years (p.a.)	Since Inception (p.a.)^^
Net^	9.53%	3.93%	22.88%	12.55%	4.67%
Benchmark*	5.76%	3.83%	9.76%	4.68%	0.56%
Alpha	3.77%	0.10%	13.12%	7.87%	4.11%

<sup>^</sup>The net return figure is calculated after fees & expenses, assuming all distributions are reinvested. Past performance is not a reliable indication of future performance.
\*\$&P/ASX Small Ordinaries Accumulation Index. ^^Inception date is 13 August 2021.

## **Key Information**

· · · · · · · · · · · · · · · · · · ·				
Portfolio Manager(s)	David Keelan & Alexandra Clarke			
Investment Objective	To outperform the Benchmark over a rolling three year period.			
Benchmark	S&P/ASX Small Ordinaries Accumulation Index			
Liquidity	Daily			
Target Number of Holdings	30-60			
Minimum Investment	Initial investment - \$10,000 Additional investment - \$5,000			
Distribution Frequency	Half-Yearly (where available)			
Management Fee	1.10% (p.a.)			
Performance Fee <sup>1</sup>	20.00%			
Buy/Sell Spread	0.25% / 0.25%			


<sup>&</sup>lt;sup>1</sup>Of the investment return above the benchmark, after recovering any underperformance in past periods.

# Top Holdings\*

Company	Sector	
Catapult Group International	Information Technology	
Life360	Information Technology	
Megaport	Information Technology	
Siteminder	Information Technology	
Superloop	Communication Services	

<sup>\*</sup>In alphabetical order. Source: Ellerston Capital.

### **Sector Allocation**



Source: Ellerston Capital.

## **Key Portfolio Metrics**

FY25e	Fund	Benchmark
Price/Earnings	16.41x	16.41x
Dividend Yield	1.91%	4.10%
Net Debt/EBITDA	-1.93x	1.20x

Source: Ellerston Capital.

### **COMMENTARY**

The Ellerston Australian Emerging Leaders Fund – Class A Units delivered 9.53% (net) in May relative to the S&P/ASX Small Ordinaries Accumulation Index which returned 5.76%. After a volatile April, May rebounded solidly shaking off "Liberation Day" as tariff deadlines were extended. Closer to home, we saw a Labor victory in the Federal Election and certainty around policies buoy equity markets coupled with a 25bps rate cut by the RBA. Around the grounds, we saw uranium stocks take off pushing the Energy sector up 12% for the month. Small Resources were also materially higher up 10% on the back of strength in the gold names. On the industrial side of the index, Information Technology rallied 9% led by Catapult (CAT AU) which was up 43% on the back of it reporting its FY25 result. We have discussed CAT numerous times in the past and it remains one of our High Conviction picks. We continue to see the announcement of new product initiatives to flow through as well as stronger operating leverage, which bodes well for FY26 and beyond.

Turning to the portfolio, two stocks which had some newsflow in May were Life  $360(360\,\text{AU})$  and Regis Healthcare (REG AU) which both reported results.

Life 360 (360 AU) reported its 1Q25 results which were ahead of market expectations across the board with better subscriber growth, higher revenue, stronger gross margin and lower operating expenses. 360 continues to execute strongly across its core US subscription business, moving both conversion and price higher in 1Q25 whilst also adding multiple further layers to growth with continued development of its international subscription business, advertising business and the upcoming release of its wearable pet tracker. We remain positive on 360 given we see its 84 million user base as significantly under monetised. For reference 360 is the 13th largest app by daily active users in the US Apple App Store but in 2024 generated US\$372m of revenue whereas no other top 20 app generated less than US\$3 billion in revenue.

Regis Healthcare (REG) gave a 3Q trading update and a conference presentation. The business is continuing to perform as expected and management were able to clearly articulate its view of the strong industry dynamics in Aged Care. Namely the Australian sector has built on average 1500 beds for the last 4 years, which compares to the government's forecasts that 10,000 beds are required to be built annually for the next 20 years. We expect this to support strong occupancy, and the government will need to improve profitability and returns in the tightly regulated sector to incentivise new builds. This means REG's existing portfolio profitability should improve, and also that REG will have opportunities to further increase growth by deploying its strong net cash balance sheet into acquisitions and greenfield developments.

Find out more:

Contact Us

Sydney

Level 11, 179 Elizabeth Street, Sydney, NSW 2000 +612 9021 7701 info@ellerstoncapital.com Should investors have any questions or queries regarding the Fund, please contact our Investor Relations team on 02 9021 7701 or info@ellerstoncapital.com or visit us at ellerstoncapital.com.

All holding enquiries should be directed to our registry, Automic Group on 1300 101 595 or ellerstonfunds@automicgroup.com.au.

This report has been prepared by Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000 (Manager), as the responsible entity of the Ellerston Australian Emerging Leaders Fund – Class A Units ARSN 647 979 333 without taking account the objectives, financial situation or needs of individuals. Before making an investment decision about the Fund, persons should read the Fund's Product Disclosure Statement and Target Market Determination (TMD) which can be obtained from the Manager's website www.ellerstoncapital.com or by contacting info@ellerstoncapital.com and obtaining advice from an appropriate financial adviser. Units in the Fund are issued by Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000. This information is current as at the date on the first page.

This material has been prepared based on information believed to be accurate at the time of publication. Assumptions and estimates may have been made which may prove not to be accurate. Ellerston Capital undertakes no responsibility to correct any such inaccuracy. Subsequent changes in circumstances may occur at any time and may impact the accuracy of the information. To the full extent permitted by law, none of Ellerston Capital Limited ABN 34 110 397 674 AFSL 283 000, or any member of the Ellerston Capital Limited Group of companies makes any warranty as to the accuracy or completeness of the information in this newsletter and disclaims all liability that may arise due to any information contained in this newsletter being inaccurate, unreliable or incomplete. Past performance is not a reliable indicator of future performance.

